Updated Jul 16, 2026
Ticho Barry has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.03M.
Barry Ticho is the Chief Medical Officer at Stoke Therapeutics, Inc., a biotechnology company focused on RNA medicine. He has been involved in multiple SEC filings related to his role, indicating a significant presence within the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 500 | $33.27 | $17K |
| 2026-07-06 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 6.7K | $32.62 | $219K |
| 2026-06-03 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 1.8K | $30.58 | $55K |
| 2026-05-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 2.2K | $32.79 | $74K |
| 2026-04-03 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.8K | $32.66 | $60K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.5K | $29.99 | $44K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | M — Option exercise [10b5-1] | 1.4K | $2.19 | $3K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 103 | $32.85 | $3K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 483 | $31.79 | $15K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 6.1K | $31.28 | $191K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.6K | $33.38 | $86K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 3.6K | $32.74 | $117K |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 10.8K | $0.00 | |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 10.0K | $0.00 | |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 13.1K | $0.00 | |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.0K | $31.35 | $62K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.7K | $31.33 | $52K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 323 | $31.32 | $10K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.4K | $30.76 | $42K |
| 2025-12-05 | STOK | Stoke Therapeutics, Inc. | M — Option exercise [10b5-1] | 10.0K | $0.00 |
Barry Ticho is the Chief Medical Officer at Stoke Therapeutics, Inc., a biotechnology company focused on RNA medicine. He has been involved in multiple SEC filings related to his role, indicating a significant presence within the company.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 25 open-market sales ($2.03M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ticho Barry profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.